Roth Capital Upgrades Halozyme Therapeutics (HALO) to Buy
Tweet Send to a Friend
Roth Capital upgraded Halozyme Therapeutics (NASDAQ: HALO) from Neutral to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
